New research challenges the prevailing hypothesis for how donor stem cell grafts cause graft-versus-host disease, or GVHD, and offers an alternative model that could guide development of novel therapies.
Jan 30, 2023
0
26
Acute Graft-versus-host disease (GvHD) is a life-threatening complication after leukemia treatment with allogeneic stem cell transplantation (i.e., the transplantation of cells from another person). GvHD occurs when the transplanted ...
Jan 17, 2023
0
26
Organ damage occurs in up to 70% of patients in the first few months following stem cell transplant. The precise reasons for this potentially life-threatening reaction have long been the subject of scientific research.
Oct 13, 2022
0
40
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression of graft-versus-host disease (GVHD) after antibiotic treatment of allogeneic hematopoietic ...
Sep 29, 2022
0
30
Researchers at Baylor College of Medicine and collaborating institutions have engineered immune cells to control two major life-threatening complications, namely graft-vs-host disease (GvHD) and cancer relapse, which typically ...
Sep 27, 2022
0
15
A new study led by UC Davis Health researchers showed that blocking IL-6 and TNF cytokines provides a more effective approach to preventing life-threatening graft-versus-host-disease (GVHD), an inflammatory condition that ...
Dec 16, 2021
0
14
A drug combination can safely prevent transplanted stem cells (graft) from attacking the recipient's (host) body, allowing them to develop into healthy new blood and immune cells, a new study shows.
Dec 13, 2021
0
49
MUSC Hollings Cancer Center researcher Yongxia Wu, Ph.D., identified a new target molecule in the fight against graft-versus-host disease (GVHD). Bone marrow transplant, a treatment for certain blood cancers, is accompanied ...
Feb 12, 2021
0
24
MUSC Hollings Cancer Center researchers found that a single strain of bacteria may be able to reduce the severity of graft-versus-host disease (GVHD), as reported online in February 2021 in JCI Insight.
Feb 11, 2021
0
19
(HealthDay)—For patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation, sitagliptin combined with tacrolimus and sirolimus results in a low incidence of grade II to IV acute graft-versus-host ...
Jan 7, 2021
0
1
